Publication:
Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis.

dc.contributor.authorMartinez-García, M A
dc.contributor.authorOscullo, G
dc.contributor.authorPosadas, T
dc.contributor.authorZaldivar, E
dc.contributor.authorVilla, C
dc.contributor.authorDobarganes, Y
dc.contributor.authorGirón, R
dc.contributor.authorOlveira, C
dc.contributor.authorMaíz, L
dc.contributor.authorGarcía-Clemente, M
dc.contributor.authorSibila, O
dc.contributor.authorGolpe, R
dc.contributor.authorRodríguez, J
dc.contributor.authorBarreiro, E
dc.contributor.authorRodriguez, J L
dc.contributor.authorFeced-Olmos, L
dc.contributor.authorPrados, C
dc.contributor.authorMuriel, A
dc.contributor.authorde la Rosa, D
dc.contributor.authorSpanish Registry of Bronchiectasis Group of SEPAR (RIBRON)
dc.date.accessioned2023-02-08T14:46:23Z
dc.date.available2023-02-08T14:46:23Z
dc.date.issued2020-04-18
dc.description.abstractThe objective of this study was to analyse lung function decline over time in bronchiectasis, along with the factors associated with it. Spirometry was measured every year in this observational, prospective study in 849 patients from the Spanish Bronchiectasis Registry (RIBRON). The main outcome was the decline in the rate of forced expiratory volume during the first second (FEV1). To be included in this study, patients needed a baseline assessment and at least one subsequent assessment. FEV1 decline was analysed using a mixed-effects linear regression model adjusted for clinically significant variables. We recruited 849 bronchiectasis patients with at least two annual lung function measurements (follow-up range 1-4 years). A total of 2262 lung function tests were performed (mean 2.66 per patient, range 2-5). Mean baseline FEV1 was 1.78 L (standard deviation (SD) 0.76; 71.3% predicted). Mean age was 69.1 (SD 15.4) years; 543 (64% women. The adjusted rates of FEV1 decline were -0.98% predicted/year (95% confidence interval (CI) -2.41 to -0.69) and -31.6 (95% CI -44.4 to -18.8) mL. The annual FEV1 decline was faster in those patients with chronic bronchial infection by Pseudomonas aeruginosa (-1.37% (52.1 mL) vs -0.37% (-24.6 mL); p  In patients with bronchiectasis, the annual rate of FEV1 decline was -31.6 mL/year and it was faster in older patients and those with chronic bronchial infection by P. aeruginosa, increased number of previous severe exacerbations and higher baseline FEV1 value.
dc.identifier.doi10.1016/j.cmi.2020.04.007
dc.identifier.essn1469-0691
dc.identifier.pmid32311472
dc.identifier.unpaywallURLhttp://www.clinicalmicrobiologyandinfection.com/article/S1198743X20302123/pdf
dc.identifier.urihttp://hdl.handle.net/10668/15396
dc.issue.number3
dc.journal.titleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
dc.journal.titleabbreviationClin Microbiol Infect
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.page.number428-434
dc.pubmedtypeJournal Article
dc.rights.accessRightsopen access
dc.subjectBronchiectasis
dc.subjectExacerbations
dc.subjectHospitalizations lung function
dc.subjectPseudomonas aeruginosa
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshBronchiectasis
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPseudomonas Infections
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshRespiratory Function Tests
dc.titlePseudomonas aeruginosa and lung function decline in patients with bronchiectasis.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number27
dspace.entity.typePublication

Files